Ishihara Soichiro, Nishikawa Takeshi, Tanaka Toshiaki, Tanaka Junichiro, Kiyomatsu Tomomichi, Kawai Kazushige, Hata Keisuke, Nozawa Hioaki, Kazama Shinsuke, Yamaguchi Hironori, Sunami Eiji, Kitayama Joji, Sugihara Kenichi, Watanabe Toshiaki
Department of Surgical Oncology, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Int J Colorectal Dis. 2015 Jun;30(6):807-12. doi: 10.1007/s00384-015-2228-4. Epub 2015 Apr 29.
Retrospective studies have shown that primary tumor resection improves the prognosis of patients with colorectal cancer (CRC) with unresectable metastasis (mCRC). The aim of this study was to investigate the prognostic impact of primary tumor resection in various subgroups of mCRC patients.
A total of 1982 patients with mCRC from January 1997 to December 2007 were retrospectively evaluated. The impact of primary tumor resection on cancer-specific survival (CSS) was analyzed using propensity score analysis to mitigate selection bias. Covariates in the models for propensity scores included treatment period, age, gender, tumor location, depth, lymph node metastasis, number of metastatic organs, and carcinoembryonic antigen (CEA) levels.
Among the whole patient population, primary tumor resection significantly improved CSS [hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.32-0.66, p < 0.01]. However, primary tumor resection did not significantly improve CSS in the following subgroups: patients treated in the first 5 years of the study (HR 0.56, 95% CI 0.28-1.13, p = 0.08), patients aged >65 years (HR 0.72, 95% CI 0.36-1.42, p = 0.31), female patients (HR 0.60, 95% CI 0.31-1.17, p = 0.13), patients with right-sided colon cancer (HR 0.68, 95% CI 0.39-1.20, p = 0.17), and patients without nodal involvement (HR 0.54, 95% CI 0.25-1.17, p = 0.09).
Our study suggests that primary tumor resection improves the survival of patients with mCRC. However, the prognostic benefit is different among patient subpopulations.
回顾性研究表明,原发肿瘤切除可改善无法切除的转移性结直肠癌(mCRC)患者的预后。本研究旨在探讨原发肿瘤切除对mCRC患者各亚组预后的影响。
回顾性评估了1997年1月至2007年12月期间共1982例mCRC患者。采用倾向评分分析来减轻选择偏倚,分析原发肿瘤切除对癌症特异性生存(CSS)的影响。倾向评分模型中的协变量包括治疗时期、年龄、性别、肿瘤位置、深度、淋巴结转移、转移器官数量和癌胚抗原(CEA)水平。
在整个患者群体中,原发肿瘤切除显著改善了CSS[风险比(HR)0.46,95%置信区间(CI)0.32 - 0.66,p < 0.01]。然而,在以下亚组中,原发肿瘤切除并未显著改善CSS:研究前5年接受治疗的患者(HR 0.56,95% CI 0.28 - 1.13,p = 0.08)、年龄>65岁的患者(HR 0.72,95% CI 0.36 - 1.42,p = 0.31)、女性患者(HR 0.60,95% CI 0.31 - 1.17,p = 0.13)、右侧结肠癌患者(HR 0.68,95% CI 0.39 - 1.20,p = 0.17)以及无淋巴结受累的患者(HR 0.54,95% CI 0.25 - 1.17,p = 0.09)。
我们的研究表明,原发肿瘤切除可改善mCRC患者的生存。然而,不同患者亚组的预后获益有所不同。